Skip to content

Search

Renowned Autism Researcher named Western Australian of the Year

Autism researcher Professor Andrew Whitehouse has been named this year’s Western Australian of the Year in the HBF Professions category.

COMPASS approach charts new direction in communication support for autistic kids

A game-changing approach to autism support that aims to have all autistic kids in Western Australia able to communicate effectively by school entry has received more than $11 million in funding.

Here's to one year at Perth Children's Hospital

It's The Kids Research Institute Australia's first anniversary within Perth Children’s Hospital

New roadmap to help families navigate support for autistic children

Australia’s first national guideline for supporting the learning, participation and wellbeing of autistic children and their families.

Learning to cope with uncertainty

A small group program to help parents tackle anxiety in young children diagnosed with autism has found significant improvements in both children’s anxiety and parental mental health and wellbeing.

Therapy for babies with signs of autism cuts long-term disability costs

New research evaluating the potential cost savings of a therapy for babies displaying early autism signs has predicted a three dollar return to Australia’s National Disability Insurance Scheme (NDIS) for every dollar invested in therapy.

Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization

Pulmonary bacterial infections present a significant health risk to those with chronic respiratory diseases including cystic fibrosis and chronic-obstructive pulmonary disease. With the emergence of antimicrobial resistance, novel therapeutics are desperately needed to combat the emergence of resistant superbugs.

Cystic fibrosis clinical isolates of aspergillus fumigatus induce similar muco-inflammatory responses in primary airway epithelial cells

Aspergillus is increasingly associated with lung inflammation and mucus plugging in early cystic fibrosis disease during which conidia burden is low and strains appear to be highly diverse. It is unknown whether clinical Aspergillus strains vary in their capacity to induce epithelial inflammation and mucus production.

Bacteriophage: A new therapeutic player to combat neutrophilic inflammation in chronic airway diseases

Persistent respiratory bacterial infections are a clinical burden in several chronic inflammatory airway diseases and are often associated with neutrophil infiltration into the lungs. Following recruitment, dysregulated neutrophil effector functions such as increased granule release and formation of neutrophil extracellular traps (NETs) result in damage to airway tissue, contributing to the progression of lung disease.

Animal-free peptones support bacteriophage propagation for therapeutic use without altering bactericidal activity or genomic integrity

Bacteriophage (phage) propagation has traditionally relied on bacterial culture media containing animal-derived ingredients; however, safety concerns with animal-derived materials for production of phages for therapeutic use limit their acceptability. We compared animal-free and traditional media formulations, and evaluated effects on phage yield, bactericidal activity, and genomic characteristics, hypothesizing no significant differences would be observed.